

CONSOLIDATED			STANDALONE			
Quarter ended on 30 th September 2011	Six months Ended on 30 th September 2011	Year Ended on 31 st March 2011	Particulars	Quarter ended on 30 th September 2011	Six months Ended on 30 th September 2011	Year Ended on 31 st March 2011
(Reviewed)	(Reviewed)	(Audited)		(Reviewed)	(Reviewed)	(Audited)
24902	45625	78805	1 (a) Net Sales / Income from Operations	24902	45625	78805
14903	28652	41859	Domestic	13616	25167	38147
39805	74277	120664	Exports	38518	70792	116952
109	254	766	Total	109	254	766
39696	74023	119898	Less : Excise Duty	38409	70538	116186
103	143	306	Net Sales / Income from Operations	103	143	306
			(b) Other Operating Income			
39799	74166	120204	Total Income	38512	70681	116492
(2,085)	(3,259)	(472)	2 Expenditure	(2,085)	(3,259)	(472)
15422	27224	43494	(a) Decrease/(increase) in stock in trade and work in progress	15422	27224	43494
6038	12583	16018	(b) Consumption of Raw Materials & Packing Materials	4841	9397	12857
3715	7660	14149	(c) Purchase of traded goods	3715	7660	14149
1309	2518	4714	(d) Employees' Cost	1309	2518	4714
243	235	664	(e) Research and Development Expense	243	235	664
9110	16123	25612	(f) Excise Duty	9017	15926	25513
33752	63084	104179	(g) Other Expenditure	32462	59701	100919
6047	11082	16025	Total	6050	10980	15573
10	18	8	3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	10	18	8
6057	11100	16033	4 Other Income	6060	10998	15581
845	1664	2959	5 Profit/(Loss) before Interest, Depreciation, & Exceptional Items	845	1664	2959
708	1385	2389	6 Depreciation	708	1385	2389
4504	8051	10685	7 Interest (Net)	4507	7949	10233
910	1633	1864	8 Profit/(Loss) after Interest but before Exceptional Items	917	1628	1801
(210)	(142)	282	9 Tax Expense	(210)	(142)	282
3804	6560	8539	Less : Provision for Current Tax	3800	6463	8150
3770	3770	3770	(Less)/Add : Provision for Deferred Tax (Liability)/Assets			
-	-	25758	10 Net Profit / (Loss) from Ordinary Activities after Tax	3770	3770	3770
-	-	2333	11 Paid up Equity Share Capital	-	-	23851
2.02	3.48	4.53	(Face value of share Rs 2/-)	-	-	2333
-	1.30	0.86	12 Reserves excluding Revaluation Reserve	2.02	3.43	4.32
-	2.06	2.76	13 Debenture Redemption Reserve	-	1.37	0.81
-	8.01	6.69	14 Basic & Diluted EPS (Not Annualised)	-	2.04	2.68
48763089	48763089	48763089	15 Debt Equity Ratio	-	7.94	6.52
25.87	25.87	25.87	16 Debt Service Coverage Ratio	48763089	48763089	48763089
			17 Interest Service Coverage Ratio	25.87	25.87	25.87
139752825	139752825	139752825	18 Public Shareholding			
100.00	100.00	100.00	- Number of Shares	139752825	139752825	139752825
74.13	74.13	74.13	- Percentage of Shareholding	100.00	100.00	100.00
			19 Promoters and Promoter Group Shareholding	74.13	74.13	74.13
			Fully Non - Encumbered			
			Number of Shares			
			Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			
			Percentage of Shares (as a % of the total share capital of the Company)			

Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website viz www.alembic-india.com.
- 2 This being the first year of the Company after the demerger becoming effective on 1st April, 2011, the comparable figures for the corresponding quarter/six months period of the previous financial year are not available and not given. However, the sales figures of the pharmaceuticals undertaking for the quarter/six months period of the previous final year are as under:
- | Particulars | (Rs.in Lacs) | | | |
|-------------|-----------------------------------|-----------------------------------|--------------------------------------|--------------------------------------|
| | For the quarter ended on 30.09.11 | For the quarter ended on 30.09.10 | For the Six months ended on 30.09.11 | For the Six months ended on 30.09.10 |
| Sales | 39805 | 32117 | 74277 | 57779 |
- 3 The trading in equity shares of the Company has commenced from 20th September, 2011 on both Bombay Stock Exchange Limited (BSE) and National Stock Exchange of India (NSE).
- 4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 5 Details of Investor's Complaints for the quarter ended on 30th September, 2011 : Unresolved at the beginning of the quarter-NIL Received during the quarter-NIL, Disposed off during the quarter-NIL, Unresolved at the end of the quarter - Nil

For Alembic Pharmaceuticals Limited



Chiraya Amin
Chairman and Managing Director

Place : Vadodara
Date : 19th Oct, 2011

Visit us at www.alembic-india.com



Statement of Assets and Liabilities

PARTICULARS	AS ON 30.09.2011 (Reviewed)
SHAREHOLDERS' FUNDS:	
a) Capital	3770
b) Reserves and Surplus	32773
LOAN FUNDS	45592
Deferred Tax Liability	395
TOTAL	82530
FIXED ASSETS	29739
INVESTMENTS	329
CURRENT ASSETS, LOANS AND ADVANCES	
(a) Inventories	29161
(b) Sundry Debtors	24437
(c) Cash and Bank Balances	1706
(d) Loan and Advances	23048
Less : Current Liabilities and Provisions :	
(a) Liabilities	24319
(b) Provisions	1571
TOTAL	82530

For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman and Managing Director

Place : Vadodara
Date : 19th October, 2011

Visit us at www.alembic-india.com